Cargando…

ATRT-17. CAR T CELL THERAPY TARGETING CLAUDIN-6 IS EFFECTIVE IN CELLULAR AND XENOGRAFT MODELS OF ATYPICAL TERATOID/RHABDOID TUMOR

Novel therapies are needed to for the treatment of atypical teratoid/rhabdoid tumor (ATRT), an aggressive brain tumor that predominantly affects young children and has an average 5-year survival under 50%. Claudin-6 (CLDN6) is a tight junction protein present during development and is expressed in u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Madsen, Peter, Stern, Allison, Dickson, Conor, Wilson, Cullen, Patterson, Luke, Harvey, Kyra, Griffin, Crystal, Oehm, Petra, Rengstl, Benjamin, Flemmig, Carina, Storm, Phillip, Resnick, Adam, Foster, Jessica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Final Category: ATRT/Embryonal/ETMR - ATRT
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259899/ http://dx.doi.org/10.1093/neuonc/noad073.017

Ejemplares similares

ATRT-16. THE PI3K INHIBITOR PAXALISIB COMBINES SYNERGISTICALLY WITH THE MEK INHIBITOR MIRDAMETINIB TO TARGET ATYPICAL TERATOID/RHABDOID TUMORS
por: Malebranche, Kristen, et al.
Publicado: (2023)

ATRT-02. AN INFANTILE PINEAL EMBRYONAL TUMOR SHOWING PATHOLOGICAL FEATURES OF A CNS GANGLIONEUROBLASTOMA IN ADDITION TO SMARCA4 MUTATIONS AND THE METHYLATION PROFILING OF AN ATYPICAL TERATOID/RHABDOID TUMOR
por: Fukuoka, Kohei, et al.
Publicado: (2023)

ATRT-09. COMBINATION OF THE PI3K INHIBITOR PAXALISIB WITH THE NUCLEOSIDE ANALOG GEMCITABINE ACTIVATES THE INTEGRATED STRESS RESPONSE AND EXTENDS SURVIVAL IN ORTHOTOPIC MODELS OF ATYPICAL TERATOID/RHABDOID TUMORS
por: Findlay, Tyler, et al.
Publicado: (2023)

ATRT-01. PARP INHIBITION AS A THERAPEUTIC TARGET IN ATRT
por: Alimova, Irina, et al.
Publicado: (2023)

ATRT-05. DNA DAMAGE REPAIR INHIBITOR LP-184 INHIBITS CELL GROWTH IN ATRT
por: Kwon, Hyuk Jean, et al.
Publicado: (2023)

ATRT-03. THE ORAL IRON-MIMETIC GALLIUM MALTOLATE INHIBITS ATRT IN VIVO – IMAGING AND HISTOLOGICAL CHARACTERIZATION
por: Al-Gizawiy, Mona, et al.
Publicado: (2023)

ATRT-15. ATRTS HIJACK EPIGENETIC MECHANISMS TO PROMOTE IMMUNOSUPPRESSION AND ESCAPE FROM NK CELL THERAPY
por: Swaminathan, Jyothishmathi, et al.
Publicado: (2023)

ATRT-11. DEVELOPMENT OF NOVEL PRECLINICAL MODELS AND THERAPEUTIC STRATEGIES FOR ETMR
por: Cocito, Carolina, et al.
Publicado: (2023)

ATRT-06. ETMR TUMORIGENESIS MIRRORS RADIAL GLIAL DEVELOPMENT
por: Yao, Fupan, et al.
Publicado: (2023)

ATRT-13. ASSESSMENT OF MITOCHONDRIAL BIOENERGETICS AND FISSION-FUSION DYNAMICS IN ETMR
por: Liapis, Evangelos, et al.
Publicado: (2023)

ATRT-14. ASSESSMENT OF MITOCHONDRIAL BIOENERGETICS AND FISSION-FUSION DYNAMICS IN ETMR
por: Liapis, Evangelos, et al.
Publicado: (2023)

ATRT-12. HYPERACTIVATING THE INTEGRATED STRESS RESPONSE WITH PROTEASOME INHIBITION IN AT/RT
por: Novak, Orlandi, et al.
Publicado: (2023)

ATRT-18. ELUCIDATING THE ETMR MICROENVIRONMENT USING SPATIAL MULTI-OMICS TECHNOLOGIES
por: Liapis, Evangelos, et al.
Publicado: (2023)

ATRT-10. SINGLE-CELL TRANSCRIPTOME ANALYSIS REVEALS CELLULAR HIERARCHIES AND THERAPEUTIC VULNERABILITIES OF ETMR
por: Beck, Alexander, et al.
Publicado: (2023)

ATRT-08. THE SINGLE-CELL LANDSCAPE OF PINEOBLASTOMA IDENTIFIES DEVELOPMENTAL ORIGINS AND EXPOSES TUMORIGENIC DEPENDENCIES
por: Gudenas, Brian, et al.
Publicado: (2023)

ATRT-07. CLINICAL APPLICABILITY OF C19MC MIRNA DETECTION IN LIQUID BIOPSIES OF ETMR PATIENTS
por: Madlener, Sibylle, et al.
Publicado: (2023)

ATRT-04. TARGETING THE COREST COMPLEX HELPS REPROGRAM AT/RT’S ABNORMAL EPIGENETIC LANDSCAPE TOWARD A DIFFERENTIATION PHENOTYPE
por: Geethadevi, Anupa, et al.
Publicado: (2023)

ATRT-19. RARE EMBRYONAL TUMORS INCLUDING EMBRYONAL TUMOR MULTILAYER ROSETTE, OUTCOME AND PATTERN OF TREATMENT FAILURE: MD ANDERSON CANCER CENTER EXPERIENCE
por: He, Jiasen, et al.
Publicado: (2023)

SDPS-18 RHABDOID TUMOR PREDISPOSITION SYNDROME IN TWO INFANT SIBLINGS WITH ATYPICAL TERATOID RHABDOID TUMORS DUE TO A GERMLINE SMARCB1 MUTATION
por: Quintero, Ana, et al.
Publicado: (2023)

SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER
por: Li, Juan, et al.
Publicado: (2023)

ATRT-05. Infants and newborns with atypical teratoid/rhabdoid tumors (ATRT) and extracranial malignant rhabdoid tumors: a unique and challenging population
por: Nemes, Karolina, et al.
Publicado: (2022)

ATRT-02. MEK/ERK SIGNALLING DEPENDENCY IN ATYPICAL TERATOID RHABDOID TUMOURS
por: Shi, Hui (Claire), et al.
Publicado: (2020)

IMMU-18. TARGETING GD2 IN THALAMIC DIFFUSE MIDLINE GLIOMA WITH TRANSIENT MRNA CAR T CELLS
por: Foster, Jessica, et al.
Publicado: (2023)

ATRT-10. ATYPICAL TERATOID/RHABDOID TUMOR OF THE PINEAL REGION IN A PEDIATRIC PATIENT
por: Almeida, Carlos, et al.
Publicado: (2020)

ATRT-18. Atypical Teratoid/Rhabdoid Tumor in Children: Case Reports from Indonesia
por: Ramadhan, Diko Anugrah, et al.
Publicado: (2022)

ATRT-05. RESULTS OF MULTICENTER TRIAL CONCERNING THE TREATMENT OF CHILDREN WITH ATYPICAL TERATOID/RHABDOID TUMORS (ATRT) OF THE CENTRAL NERVOUS SYSTEM
por: Zheludkova, Olga, et al.
Publicado: (2020)

ATRT-07. HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AN ADULT PRESENTATION OF THE ATYPICAL TERATOID-RHABDOID TUMOR (ATRT)
por: Mrugala, Maciej, et al.
Publicado: (2020)

ATRT-06. Atypical Teratoid Rhabdoid Tumors (ATRT): results from a Single Institution in Brazil - São Paulo University
por: Barreto, Juliana Silveira, et al.
Publicado: (2022)

ATRT-09. IDENTIFICATION OF HUB GENES IN ATYPICAL TERATOID/RHABDOID TUMORS BY MULTIPLE-MICROARRAY ANALYSIS
por: Liu, Wei, et al.
Publicado: (2020)

ATRT-18. SHH-SUBTYPE ATYPICAL TERATOID/RHABDOID TUMORS ARE SELECTIVELY SENSITIVE TO GEMCITABINE TREATMENT
por: Metselaar, Dennis, et al.
Publicado: (2020)

Atypical Teratoid Rhabdoid Tumors (ATRT): King Faisal Specialist Hospital and Research Centre experience
por: Mousa, Amr, et al.
Publicado: (2021)

ATRT-07. DEFINING LOST AND GAINED TRANSCRIPTIONAL REGULATORY NETWORKS IN ATYPICAL TERATOID RHABDOID TUMOR
por: Nesvick, Cody, et al.
Publicado: (2021)

ATRT-26. META-ANALYSIS OF TREATMENT MODALITIES IN METASTATIC ATYPICAL TERATOID/RHABDOID TUMORS IN CHILDREN
por: Underiner, Reena M, et al.
Publicado: (2020)

Sustained and durable response with Alisertib monotherapy in the treatment of relapsed Atypical Teratoid Rhabdoid Tumor (ATRT)
por: Howden, Kaitlyn, et al.
Publicado: (2022)

ATRT-04. INHERITED RHABDOID PREDISPOSITION SYNDROME: A CASE OF CHOROID PLEXUS CARCINOMA AND ATYPICAL TERATOID RHABDOID TUMOR IN SIBLINGS
por: Judd, Alexis, et al.
Publicado: (2020)

ATRT-06. SMARCB1 LOSS DRIVEN NON-CANONICAL PRC1 ACTIVITY REGULATES DIFFERENTIATION IN ATYPICAL TERATOID RHABDOID TUMORS (ATRT)
por: Alimova, Irina, et al.
Publicado: (2020)

ATRT-30. RETROSPECTIVE ANALYSIS OF CHILDREN WITH ATYPICAL TERATOID RHABDOID TUMOR TREATED ACCORDING TO ACNS0333
por: Hoffman, Lindsey, et al.
Publicado: (2020)

ATRT-21. RHABDOID PREDISPOSITION SYNDROME: REPORT OF MOLECULAR PROFILES AND TREATMENT APPROACH IN THREE CHILDREN WITH SYNCHRONOUS ATYPICAL TERATOID/RHABDOID TUMOR AND MALIGNANT RHABDOID TUMOR
por: Shatara, Margaret, et al.
Publicado: (2020)

IMMU-17. DEVELOPMENT OF AN INTRACRANIAL CANNULA IMPLANTATION SYSTEM FOR SERIAL LOCOREGIONAL CAR T CELL INFUSIONS IN MICE
por: Harvey, Kyra, et al.
Publicado: (2023)

ATRT-01. IDENTIFICATION OF MICRORNA-BASED PROGNOSTIC BIOMARKERS AND CANDIDATE THERAPEUTIC AGENTS FOR ATYPICAL TERATOID/RHABDOID TUMOR
por: Zhang, Yang
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ukhvl4gr3u0jpcsv0b1to28432